Boundless Bio Common Stock Performance
| BOLD Stock | USD 1.26 0.01 0.79% |
The firm shows a Beta (market volatility) of 0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Boundless Bio's returns are expected to increase less than the market. However, during the bear market, the loss of holding Boundless Bio is expected to be smaller as well. At this point, Boundless Bio Common has a negative expected return of -0.2%. Please make sure to confirm Boundless Bio's day median price, price action indicator, as well as the relationship between the accumulation distribution and potential upside , to decide if Boundless Bio Common performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Boundless Bio Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
1 | BODEGAS LAN UNVEILS BOLD REBRAND TO REFLECT A CONTEMPORARY VISION | 11/20/2025 |
2 | Acquisition by Patterson Matthew R of 4000 shares of Boundless Bio, at 2.19 subject to Rule 16b-3 | 12/16/2025 |
3 | Aquablu Makes U.S. Debut at CES 2026 with Aquablu BOLD, Launching Personalized Hydration at Scale | 01/06/2026 |
4 | 21Shares Lists Bitcoin-and-Gold BOLD ETP on London Stock Exchange | 01/13/2026 |
5 | Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway | 01/20/2026 |
| Begin Period Cash Flow | 24.3 M | |
| Total Cashflows From Investing Activities | -26.1 M |
Boundless | Build AI portfolio with Boundless Stock |
Boundless Bio Relative Risk vs. Return Landscape
If you would invest 146.00 in Boundless Bio Common on October 28, 2025 and sell it today you would lose (20.00) from holding Boundless Bio Common or give up 13.7% of portfolio value over 90 days. Boundless Bio Common is currently does not generate positive expected returns and assumes 2.9455% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Boundless, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Boundless Bio Target Price Odds to finish over Current Price
The tendency of Boundless Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.26 | 90 days | 1.26 | about 42.79 |
Based on a normal probability distribution, the odds of Boundless Bio to move above the current price in 90 days from now is about 42.79 (This Boundless Bio Common probability density function shows the probability of Boundless Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Boundless Bio has a beta of 0.57 suggesting as returns on the market go up, Boundless Bio average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Boundless Bio Common will be expected to be much smaller as well. Additionally Boundless Bio Common has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Boundless Bio Price Density |
| Price |
Predictive Modules for Boundless Bio
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Boundless Bio Common. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Boundless Bio Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Boundless Bio is not an exception. The market had few large corrections towards the Boundless Bio's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Boundless Bio Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Boundless Bio within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.16 | |
β | Beta against Dow Jones | 0.57 | |
σ | Overall volatility | 0.11 | |
Ir | Information ratio | -0.06 |
Boundless Bio Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Boundless Bio for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Boundless Bio Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Boundless Bio Common generated a negative expected return over the last 90 days | |
| Boundless Bio Common may become a speculative penny stock | |
| Boundless Bio Common has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (65.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Boundless Bio Common currently holds about 351.46 M in cash with (60.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway |
Boundless Bio Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Boundless Stock often depends not only on the future outlook of the current and potential Boundless Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Boundless Bio's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 17 M | |
| Cash And Short Term Investments | 152.1 M |
Boundless Bio Fundamentals Growth
Boundless Stock prices reflect investors' perceptions of the future prospects and financial health of Boundless Bio, and Boundless Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Boundless Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (39.61 M) | ||||
| Shares Outstanding | 22.39 M | ||||
| Price To Earning | (7.22) X | ||||
| Price To Book | 0.26 X | ||||
| EBITDA | (64.28 M) | ||||
| Net Income | (65.36 M) | ||||
| Cash And Equivalents | 351.46 M | ||||
| Cash Per Share | 7.68 X | ||||
| Total Debt | 47.63 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 12.80 X | ||||
| Book Value Per Share | 4.92 X | ||||
| Cash Flow From Operations | (60.84 M) | ||||
| Earnings Per Share | (2.66) X | ||||
| Market Capitalization | 28.21 M | ||||
| Total Asset | 206.41 M | ||||
| Retained Earnings | (201.47 M) | ||||
| Working Capital | 146.25 M | ||||
| Current Asset | 99.64 M | ||||
| Current Liabilities | 104 K | ||||
About Boundless Bio Performance
By analyzing Boundless Bio's fundamental ratios, stakeholders can gain valuable insights into Boundless Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Boundless Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Boundless Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Boundless Bio Common performance evaluation
Checking the ongoing alerts about Boundless Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Boundless Bio Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Boundless Bio Common generated a negative expected return over the last 90 days | |
| Boundless Bio Common may become a speculative penny stock | |
| Boundless Bio Common has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (65.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Boundless Bio Common currently holds about 351.46 M in cash with (60.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway |
- Analyzing Boundless Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Boundless Bio's stock is overvalued or undervalued compared to its peers.
- Examining Boundless Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Boundless Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Boundless Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Boundless Bio's stock. These opinions can provide insight into Boundless Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Boundless Stock analysis
When running Boundless Bio's price analysis, check to measure Boundless Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boundless Bio is operating at the current time. Most of Boundless Bio's value examination focuses on studying past and present price action to predict the probability of Boundless Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boundless Bio's price. Additionally, you may evaluate how the addition of Boundless Bio to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |